PharmaShots | Incisive News in 3 Shots

Subscribe Now

malignant pleural mesothelioma

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelioma

BMS' Opdivo (nivolumab) + Yervoy (ipilimumab) Receive EC's Approval for 1L Treatment for Unresectable Malignant Pleural Mesothelio...

June 3, 2021

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelioma

ONO and BMS' Opdivo + Yervoy Receive Approval for 1L Treatment for Unresectable Advanced or Recurrent Malignant Pleural Mesothelio...

May 28, 2021

Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma

Targovax Receives US FDA's Fast Track Designation for ONCOS-102 for Malignant Pleural Mesothelioma

February 16, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us